Enhancing tumor specific immune responses by transcutaneous vaccination
Introduction: Our understanding of the involvement of the immune system in cancer control has increased over recent years. However, the development of cancer vaccines intended to reverse tumor-induced immune tolerance remains slow as most current vaccine candidates exhibit limited clinical efficacy....
Saved in:
Main Authors: | Hanadi Saliba (Author), Béatrice Heurtault (Author), Hasnaa Bouharoun-Tayoun (Author), Vincent Flacher (Author), Benoît Frisch (Author), Sylvie Fournel (Author), Soulaima Chamat (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2017-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Protection of medical and paramedical university students in Lebanon against measles, mumps, rubella and varicella: Active measures are needed
by: Soulaima Chamat, et al.
Published: (2011) -
Adjuvant DNA vaccine pNMM promotes enhanced specific immunity and anti-tumor effects
by: Yu Wang, et al.
Published: (2023) -
Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
Published: (2019) -
Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity
by: Bin Tu, et al.
Published: (2022) -
Development of a transcutaneous form of desloratadine
by: Valentin P. Ageev, et al.
Published: (2024)